Evidence map›Paper›PMID 38428643›Full record

ArticleJournal of hepatology2024

PTEN deficiency induces an extrahepatic cholangitis-cholangiocarcinoma continuum via aurora kinase A in mice.

Yan Yang, Jiale Wang, Jianhua Wan, Qianqian Cheng, Zenong Cheng, Xueli Zhou, Oliver Wang, Kelvin S.Y. Shi, Lingxiang Wang, Bin Wang and 23 more

Open access · greenAbstract read
In one paragraph

Article in Journal of hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 7 institutions in 2 countries.

Yan YangDepartment of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA; Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Jiale WangDepartment of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA.
Jianhua WanDepartment of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA.
Qianqian ChengDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Zenong ChengDepartment of Pathology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Xueli ZhouDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Oliver WangDepartment of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA.
Kelvin S.Y. ShiDepartment of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA.
Lingxiang WangDepartment of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA.
Bin WangDepartment of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA.
Xiaohui ZhuDepartment of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA.
Jiaxiang ChenDepartment of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA.
Dongfeng FengDepartment of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA.
Yang LiuDepartment of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA.
Yasmin Jahan-MihanDepartment of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA.
Ashley N HaddockDepartment of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA.
Brandy H EdenfieldDepartment of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA.
Guang PengDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jessica D HohensteinDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
Chantal E McCabeDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
Daniel R O'BrienDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
Chen WangDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
Sumera I IlyasDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Liuyan JiangDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida, USA.
Michael S TorbensonDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Huamin WangDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Raouf E NakhlehDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida, USA.
Xuemei ShiGreenwood Genetic Center, Greenwood, South Carolina, USA.
Ying WangDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Yan BiDepartment of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.
Gregory J GoresDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Tushar PatelDepartment of Transplantation, Mayo Clinic, Jacksonville, Florida, USA.
Baoan JiDepartment of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA. Electronic address: ji.baoan@mayo.edu.
Mayo Clinic in Florida · USJacksonville College · USMayo Clinic · USFirst Affiliated Hospital of Bengbu Medical College · CNThe University of Texas MD Anderson Cancer Center · USGreenwood Genetic Center · USWinnMed · US

Funding

Project 4: ImmunovirotherapyP50CA210964 · NCI · MAYO CLINIC ROCHESTER · PI Zongming Eric Chen · 2018 to 2026
$20.5M
Mechanisms of Hereditary PancreatitisR01DK117910 · NIDDK · MAYO CLINIC JACKSONVILLE · PI Baoan Ji, Ying Wang · 2019 to 2026
$3.5M
PRSS1 Mutation and Pancreatic Cancer TumorigenesisR01CA255068 · NCI · MAYO CLINIC JACKSONVILLE · PI JI, BAOAN · 2021 to 2025
$2.2M
NCI NIH HHS P50 CA210964NCI NIH HHS R01 CA255068NIDDK NIH HHS R01 DK117910
6 · The paper itself

Abstract

BACKGROUND &

aimsThe PTEN-AKT pathway is frequently altered in extrahepatic cholangiocarcinoma (eCCA). We aimed to evaluate the role of PTEN in the pathogenesis of eCCA and identify novel therapeutic targets for this disease.

methodsThe Pten gene was genetically deleted using the Cre-loxp system in biliary epithelial cells. The pathologies were evaluated both macroscopically and histologically. The characteristics were further analyzed by immunohistochemistry, reverse-transcription PCR, cell culture, and RNA sequencing. Some features were compared to those in human eCCA samples. Further mechanistic studies utilized the conditional knockout of Trp53 and Aurora kinase A (Aurka) genes. We also tested the effectiveness of an Aurka inhibitor.

resultsWe observed that genetic deletion of the Pten gene in the extrahepatic biliary epithelium and peri-ductal glands initiated sclerosing cholangitis-like lesions in mice, resulting in enlarged and distorted extrahepatic bile ducts in mice as early as 1 month after birth. Histologically, these lesions exhibited increased epithelial proliferation, inflammatory cell infiltration, and fibrosis. With aging, the lesions progressed from low-grade dysplasia to invasive carcinoma. Trp53 inactivation further accelerated disease progression, potentially by downregulating senescence. Further mechanistic studies showed that both human and mouse eCCA showed high expression of AURKA. Notably, the genetic deletion of Aurka completely eliminated Pten deficiency-induced extrahepatic bile duct lesions. Furthermore, pharmacological inhibition of Aurka alleviated disease progression.

conclusionsPten deficiency in extrahepatic cholangiocytes and peribiliary glands led to a cholangitis-to-cholangiocarcinoma continuum that was dependent on Aurka. These findings offer new insights into preventive and therapeutic interventions for extrahepatic CCA. IMPACT AND IMPLICATIONS: The aberrant PTEN-PI3K-AKT signaling pathway is commonly observed in human extrahepatic cholangiocarcinoma (eCCA), a disease with a poor prognosis. In our study, we developed a mouse model mimicking cholangitis to eCCA progression by conditionally deleting the Pten gene via Pdx1-Cre in epithelial cells and peribiliary glands of the extrahepatic biliary duct. The conditional Pten deletion in these cells led to cholangitis, which gradually advanced to dysplasia, ultimately resulting in eCCA. The loss of Pten heightened Akt signaling, cell proliferation, inflammation, fibrosis, DNA damage, epigenetic signaling, epithelial-mesenchymal transition, cell dysplasia, and cellular senescence. Genetic deletion or pharmacological inhibition of Aurka successfully halted disease progression. This model will be valuable for testing novel therapies and unraveling the mechanisms of eCCA tumorigenesis.

Indexed as

Aurora Kinase ABile Duct NeoplasmsCholangiocarcinomaPTEN PhosphohydrolaseAnimalsBile Ducts, ExtrahepaticCholangitisDisease Models, AnimalHumansMiceMice, KnockoutSignal TransductionTumor Suppressor Protein p53AURKA protein, humanAurka protein, mouseAurora Kinase APTEN PhosphohydrolasePTEN protein, humanPten protein, mouseTrp53 protein, mouseTumor Suppressor Protein p53AKTBiliary cancerCell of originEMTInflammationPTEN

Identifiers

PMID38428643
PMCPMC11259013
OpenAlexW4392245519

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.